BioInvent International AB (publ) (STO:BINV)
Sweden · Delayed Price · Currency is SEK 24.50
+1.45 (6.29%)
Sep 2, 2026, 5:29 PM CET
STO:BINV Revenue
BioInvent International AB had revenue of 12.75M SEK in the quarter ending June 30, 2026, a decrease of -93.56%. This brings the company's revenue in the last twelve months to 32.51M, down -46.84% year-over-year. In the year 2025, BioInvent International AB had annual revenue of 226.50M with 406.86% growth.
Revenue (ttm)
32.51M
Revenue Growth
-46.84%
P/S Ratio
46.66
Revenue / Employee
301.02K
Employees
108
Market Cap
1.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 226.50M | 181.81M | 406.86% |
| Dec 31, 2024 | 44.69M | -26.78M | -37.47% |
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
| Dec 31, 2020 | 147.37M | 53.63M | 57.21% |
| Dec 31, 2019 | 93.74M | 55.19M | 143.18% |
| Dec 31, 2018 | 38.55M | -6.47M | -14.36% |
| Dec 31, 2017 | 45.01M | -26.27M | -36.85% |
| Dec 31, 2016 | 71.28M | 55.36M | 347.62% |
| Dec 31, 2015 | 15.93M | -31.01M | -66.07% |
| Dec 31, 2014 | 46.93M | -34.78M | -42.56% |
| Dec 31, 2013 | 81.71M | 38.77M | 90.27% |
| Dec 31, 2012 | 42.95M | -81.70M | -65.55% |
| Dec 31, 2011 | 124.65M | 41.78M | 50.42% |
| Dec 31, 2010 | 82.87M | 2.21M | 2.74% |
| Dec 31, 2009 | 80.66M | -171.48M | -68.01% |
| Dec 31, 2008 | 252.14M | 108.70M | 75.78% |
| Dec 31, 2007 | 143.44M | 92.61M | 182.20% |
| Dec 31, 2006 | 50.83M | 22.63M | 80.26% |
| Dec 31, 2005 | 28.20M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 424.56M |
| Genovis AB (publ.) | 136.99M |
| AlzeCure Pharma AB | 97.33M |
| Oncopeptides AB | 95.15M |
| Egetis Therapeutics AB | 66.00M |
| Medivir AB | 8.71M |
| Vicore Pharma Holding AB | 3.99M |
| FluoGuide | 404.33K |
BioInvent International AB News
- 6 days ago - BioInvent International AB Quarterly report: Q2 2026 - Filings
- 13 days ago - BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research - Accesswire
- 26 days ago - BioInvent International: BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer - Finanz Nachrichten
- 26 days ago - BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer - Accesswire
- 5 weeks ago - BioInvent International: BioInvent Publication in JECCR: Tailored Fc?R Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models - Finanz Nachrichten
- 5 weeks ago - BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models - Accesswire
- 6 weeks ago - BioInvent International: BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026 - Finanz Nachrichten
- 6 weeks ago - BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026 - Accesswire